Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Maternal Inclusion Criteria:~* Participant must belong to one of the following 5 groups:~  1. HIV-infected pregnant women greater than or equal to 20 weeks gestation NOT on TB treatment receiving one or more of the ARV drugs/drug combinations specified in the protocol~ 2. HIV-infected pregnant women greater than or equal to 20 weeks gestation receiving one of the ARV drugs/drug combinations specified in the protocol and TB treatment with at least one of the TB drugs, specified in the protocol, at study entry~ 3. HIV-uninfected pregnant women greater than or equal to 20 weeks gestation receiving at least two of the first-line TB drugs, specified in the protocol, at study entry~ 4. HIV-infected and HIV-uninfected pregnant women greater than or equal to 20 weeks gestation receiving at least two of the second-line TB drugs, specified in the protocol, at study entry~ 5. HIV-infected women 2 to 12 weeks (14 to 84 days) post-delivery receiving one of the ARV drug combinations listed in the protocol AND starting postpartum contraceptives as listed in the protocol~* The woman must be stable on the ARV drug/drug combination and/or TB drug combination for at least 2 weeks prior to PK sampling~* If a woman is receiving a specific generic ARV formulation, the protocol team has approved this formulation~* HIV-infected pregnant women must be planning to continue on current ARV regimen until postpartum PK sampling is completed. HIV-infected postpartum women on hormonal contraceptives must be planning to continue on ARV and contraceptive regimens until final PK sampling is completed~* For HIV-infected women: confirmed HIV infection, documented by positive results from two samples collected at different time points prior to study entry. More information on this criterion can be found in the protocol.~* HIV-uninfected pregnant women must have documented negative HIV antibody test during current pregnancy. Note: adequate source documentation, including the date of specimen collection, date of testing, test performed, and test result, must be available.~* Participants enrolling in the 3rd trimester must enroll by 37 6/7 weeks gestation~* Participant can provide legal informed consent per local regulations~* If a woman has completed this study and becomes pregnant again, she may re-enroll in the study only if she is enrolled in a different arm than that studied during her initial enrollment~Maternal Exclusion Criteria:~* Women on medicines known to interfere with absorption, metabolism, or clearance of the drug being evaluated (see protocol for more information). Rifampicin is permitted for women being evaluated for TB and ARV drug interactions~* If pregnant, carrying multiple fetuses~* Clinical or laboratory toxicity that, in the opinion of the site investigator, would be likely to require a change in the medicine regimen during the period of study~Infant Enrollment Criteria:~- All infants of mothers enrolled during pregnancy (meeting criteria specified above) are enrolled, in utero, immediately after maternal enrollment.~Infant Requirements for Washout Pharmacokinetic Sampling:~* Born to HIV-infected mother enrolled during pregnancy in an ARV arm (does not include infants born to HIV-uninfected mothers receiving TB drugs)~* Birth weight greater than 1000 grams~* Is NOT receiving disallowed medications described in Section 7 of the protocol~* Does not have any severe congenital malformation or other medical condition not compatible with life or that would interfere with study participation or interpretation, as judged by the site investigator~* Born after singleton delivery (not after multiple birth)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DRV/RTV 600 or 800 or 900/100mg b.i.d. then 800 or 900/100mg b.i.d. then 600/100mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received:~darunavir/ritonavir (DRV/RTV) 600/100 mg twice daily (b.i.d.) or 800/100 mg b.i.d. until 30 weeks gestation; then 800/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn.~OR darunavir/ritonavir twice daily 600/100 mg b.i.d. or 900/100 mg b.i.d. until 30 weeks gestation; then 900/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn.
- DTG 50mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received dolutegravir (DTG) 50 mg once a day (q.d.).
- TAF 25mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. without cobicistat or ritonavir boosting.
- TAF 10mg q.d. w/COBI (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 10 mg q.d. with cobicistat (COBI).
- TAF 25mg q.d. w/COBI or RTV boosting (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. with cobicistat (COBI) or ritonavir (RTV) boosting.
- EVG/COBI 150/150mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received elvitegravir/cobicistat (EVG/COBI) 150/150 mg q.d
- DRV/COBI 800/150 mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d.
- ATV/COBI 300/150 mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d.
- EFV 600 mg q.d. (outside THA) (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received efavirenz (EFV) 600 mg q.d. (Participants outside of Thailand only)
- EFV 600mg q.d. and at least one 1st line TB drug (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600mg q.d.and TB treatment with at least one of the following TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
- LPV/RTV 800/200mg b.i.d. and at least one 1st line TB drug (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 800/200mg b.i.d. and TB treatment with at least one of the following TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
- No ARVs and at least two 1st line TB drugs (Type: None): HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following first line TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
- At least two 2nd line TB drugs w/ or w/out ARVs (Type: None): HIV-infected and HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following second line TB drugs at study entry:~Injectable agents:~* kanamycin~* amikacin~* capreomycin~Fluoroquinolones:~* moxifloxacin~* levofloxacin~* ofloxacin~Oral bacteriostatic second-line agents:~* ethionamide/prothionamide~* terizidone/cycloserine~* para-aminosalicylic acid (PAS)~Other agents:~* high dose INH~* bedaquiline~* clofazamine~* delamanid~* linezolid~* pretomanid
- DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with 30-35ug EE (Type: None): HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol
- DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with ENG (Type: None): HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting etonogestrel (ENG) implant
- EFV 600mg q.d. with 30-35ug EE (Type: None): HIV-infected women 2-12 weeks (14-84 days) post-delivery who received efavirenz (EFV) 600mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
- ATV/RTV/TFV 300/100/300mg q.d. with 30-35ug EE (Type: None): HIV-infected women 2-12 weeks (14-84 days) post-delivery who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
- NVP 200mg b.i.d (Type: None): HIV-infected pregnant women ≥ 26 weeks gestation who received nevirapine (NVP) 200 mg twice a day
- APV 1200mg b.i.d (Type: None): HIV-infected pregnant women ≥ 26 weeks gestation who received amprenavir (APV) 1200mg twice a day
- ABC 300mg b.i.d (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received abacavir (ABC) 300mg twice a day
- LPV/RTV Arm 1: 400/100mg b.i.d (Type: None): HIV-infected pregnant women ≥ 26 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 400/100mg twice a day
- IDV/RTV Arm 1: 800/100mg b.i.d (Type: None): HIV-infected pregnant women ≥ 26 weeks gestation who received indinavir/ritonavir (IDV/RTV) 800/100 mg twice a day
- FPV/RTV 700/100mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received fosamprenavir/ritonavir (FPV/RTV)700/100mg twice a day
- LPV/RTV Arm 2: 400/100mg b.i.d. then 533/133mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received Kaletra (LPV/RTV) 400/100 mg twice a day until 30 weeks gestation, then 533/133 mg twice a day until results of postpartum PK evaluation were available
- ATV/RTV Arm 1: 300/100mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day
- DDI 400mg or 250mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received didanosine delayed release (Videx® EC) (DDI) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
- FTC 200mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received emtricitabine (FTC) 200 mg once a day
- TFV 300mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir (TFV) 300 mg once a day
- TFV/ATV/RTV Arm 1: 300/300/100mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day
- NFV Arm 1: 1250mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) \[625 mg tablets\] 1250 mg twice a day
- EFV 600mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600 mg once a day
- TPV/RTV 500/200mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received tipranavir/ritonavir (TPV/RTV) 500/200 mg twice a day
- LPV/RTV Arm 3: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) tablets 400/100 mg \[2 tablets\] twice a day until 30 weeks gestation, then 600/150 mg \[3 tablets\] twice a day until postpartum hospital discharge; and 400/100 mg \[2 tablets\] twice a day after postpartum hospital discharge, until 2 week postpartum PK sample is drawn
- RAL 400mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received raltegravir (RAL) 400 mg twice a day
- ETR 200mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received etravirine (ETR) 200mg twice a day
- MVC 150 or 300mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received maraviroc (MVC)150 mg or 300 mg twice a day
- DRV/RTV 800/100mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 800/100 mg once a day
- DRV/RTV 600/100mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 600/100 mg twice a day
- ATV/RTV Arm 2: 300/100mg q.d. then 400/100mg q.d. then 300/100mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day until 30 weeks gestation then 400/100 mg once a day until postpartum hospital discharge; then 300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
- TFV/ATV/RTV Arm 2: 300/300/100mg q.d. then 300/400/100mg q.d then 300/300/100mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day until 30 weeks gestation; then 300/400/100 mg once a day until postpartum hospital discharge; then 300/300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
- NFV Arm 2: 1250mg b.i.d. then 1875mg b.i.d. then 1250mg b.i.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) \[625 mg tablets\] 1250 mg twice a day until 30 weeks gestation; then 1875 mg twice a day until postpartum hospital discharge; then 1250 mg twice a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
- IDV/RTV Arm 2: 400/100mg q.d. (only THA) (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received indinavir/ritonavir (IDV/RTV) 400/100 mg twice a day only to participants enrolling in Thailand
- LPV/RTV Arm 4: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d. (only African sites) (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV, Alluvia tablets) 400/100 mg \[2 tablets\] twice day until 30 weeks gestation; then 600/150 mg \[3 tablets\] twice a day until postpartum hospital discharge; then 400/100 mg \[2 tablets\] twice a day after postpartum hospital discharge until 2 week postpartum PK sample drawn only to participants enrolling in Uganda
- RPV 25mg q.d. (Type: None): HIV-infected pregnant women ≥ 20 weeks gestation who received rilpivirine (RPV) (25 mg q.d.)
- NVP 200mg b.i.d. and RIF and at least one 1st line TB drug (Type: None): HIV-infected pregnant women \> 20 weeks gestation who received nevirapine (NVP) 200 mg b.i.d AND rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w. and at least one of the following drugs at study entry:~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
- ATV/RTV/TFV 300/100/300mg q.d. with ENG (Type: None): HIV- infected women 2-12 weeks postpartum who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant
- LPV/RTV 400/100 b.i.d. with 30-35ug EE (Type: None): HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
- LPV/RTV 400/100 b.i.d. with ENG (Type: None): HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting postpartum etonogestrel (ENG) implant
- EFV 600mg q.d. with ENG (Type: None): HIV-infected women 2-12 weeks postpartum who received efavirenz (EFV) 600mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete